Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 19 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (5)
Early P 1 (1)
P 2 (3)

Trial Status

Recruiting6
Completed5
Not Yet Recruiting4
Enrolling By Invitation3
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07569367Not Yet Recruiting

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

NCT07200739Not Yet Recruiting

Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)

NCT07333898Not Yet Recruiting

Digital Measurements of Motor and Voice Functions in FTD

NCT07239843Enrolling By Invitation

Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders

NCT02912936Not ApplicableCompleted

A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease

NCT07505784Not ApplicableRecruiting

Transcranial Alternating Current Stimulation in Frontotemporal Dementia

NCT06856850Recruiting

Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

NCT06604520Phase 2Recruiting

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

NCT07314190Enrolling By Invitation

Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder

NCT03402919Recruiting

Comprehensive Assessment of Neurodegeneration and Dementia

NCT07307872Completed

A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease

NCT06978946Not ApplicableNot Yet Recruiting

Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients

NCT06891716Early Phase 1RecruitingPrimary

[18F]ACI-19626 PET in TDP-43 Proteinopathies

NCT06711510Not ApplicableWithdrawnPrimary

Predict to Prevent PGRN Disease

NCT06803784Recruiting

Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders

NCT06826157Not ApplicableEnrolling By Invitation

The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias

NCT02862210Phase 2CompletedPrimary

Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia

NCT02365922Completed

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02676843Phase 2Completed

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Showing all 19 trials

Research Network

Activity Timeline